Cardarine GW-501516: What Researchers Need to Know in 2026

Few compounds in the research world have generated as much scientific interest — and controversy — as Cardarine, also known as GW-501516 or GW1516. Originally developed in the early 1990s through a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals, this selective PPARδ agonist was studied for its potential in treating metabolic disease, dyslipidemia, and cardiovascular conditions. Its development was later halted after preclinical cancer findings, yet the compound remains one of the most actively researched non-approved substances in the world.

This overview covers the current state of research on GW-501516, what the literature says about its mechanisms and observed effects, and where ongoing investigation stands in 2026.

What Is Cardarine (GW-501516)?

Cardarine is a synthetic compound that acts as a selective agonist of the Peroxisome Proliferator-Activated Receptor Delta (PPARδ), a nuclear receptor involved in regulating gene expression related to lipid metabolism, energy homeostasis, and inflammation. Unlike SARMs, GW-501516 is not a selective androgen receptor modulator — it targets PPARδ specifically, influencing how cells generate and use energy at the mitochondrial level.

PPARδ receptors are highly expressed in metabolically active tissues: skeletal muscle, cardiac muscle, liver, and neurons. Activation of these receptors shifts the body’s fuel preference away from glucose and toward fatty acid oxidation — a mechanism that has drawn attention from researchers studying metabolic disorders, exercise physiology, and neurological function.

Research Overview

Scientific interest in GW-501516 spans multiple fields. A 2023 review published in Genetics & Molecular Medicine summarized that PPARδ activation via GW-501516 stimulates mitochondrial function across tissues, improves lipid metabolism, and demonstrates potential in conditions including dyslipidemia, type-2 diabetes mellitus, and cardiovascular fibrosis (Bianchi et al., 2023). The review also noted that Cardarine appears to suppress β-amyloid deposition in preclinical models, raising interest in neurological applications.

A clinical study reviewed in the Journal of Health, Sports, and Kinesiology (Park et al., 2021) reported that GW-501516 treatment ameliorated multiple metabolic syndrome abnormalities — including oxidative stress, obesity markers, dyslipidemia, and insulin resistance — while increasing fatty acid oxidation in an 18-subject cohort (Park et al., 2021).

On PubMed, GW-501516 has over 150 indexed research entries spanning pharmacology, toxicology, exercise science, and metabolic medicine. Notable searches include GW501516 PPARδ studies on PubMed and Google Scholar results on endurance and fat oxidation. For community discussion, the r/Peptides subreddit hosts ongoing documentation of research experiences with GW-501516.

Potential Benefits Studied

• Enhanced fatty acid oxidation: PPARδ activation shifts cellular energy preference from glucose to lipids, increasing fat-burning capacity in skeletal and cardiac muscle.
• Improved metabolic syndrome markers: Clinical-adjacent research has observed improvements in dyslipidemia, triglyceride levels, and insulin sensitivity.
• Endurance enhancement: Preclinical models have demonstrated significant increases in exercise capacity via mitochondrial biogenesis — earning GW-501516 a WADA ban since 2009 under the S4.5 Metabolic Modulators class.
• Cardiovascular tissue effects: Research suggests PPARδ activation may reduce cardiac fibrosis and improve cardiomyocyte function.
• Liver fat reduction: Studies in animal models indicate reduction in hepatic fat deposits and suppression of inflammatory pathways.
• Neurological interest: Emerging research points to potential in preventing β-amyloid accumulation associated with Alzheimer’s disease pathology.

Dosage & Administration in Research Contexts

In published research and pharmacokinetic studies, GW-501516 has been administered orally. The compound is characterized by good oral bioavailability, a half-life estimated at 16–24 hours, and distribution into target metabolic tissues. Research protocols have examined dosing in the 5–20mg range administered once daily. Hair analysis studies (Kintz et al., 2020) have detected GW-501516 in subjects who self-reported 10–20mg per day orally over 6–8 week periods.

It is important to note that GW-501516 has no approved therapeutic use in any jurisdiction. All dosing data cited here comes from published toxicological, pharmacokinetic, or research contexts and is presented for informational purposes only.

Where to Find It

Cardarine GW-501516 10mg is available for research purposes at combatresearch.is. Combat Research stocks pharmaceutical-grade research compounds with documented quality standards.

Conclusion

Cardarine GW-501516 remains one of the most compelling research compounds in the metabolic and exercise science space. Its mechanism — selective PPARδ agonism driving mitochondrial biogenesis and fatty acid oxidation — is well-characterized in preclinical literature, with early human studies suggesting meaningful metabolic effects. The cancer controversy, rooted in high-dose/long-duration animal models, continues to be a critical consideration for any research design. As of 2026, academic interest remains active across metabolic disease, sports physiology, and neurological research.

Researchers interested in PPARδ biology and metabolic modulation will find GW-501516 a scientifically rich compound with a substantial existing literature base to build from.

Disclaimer: This article is intended for educational and informational purposes only. GW-501516 is not approved by the FDA or any regulatory body for human use. This content does not constitute medical advice, diagnosis, or treatment. Combat Research compounds are sold strictly for research purposes.